Show simple item record

dc.contributor.authorKhodadadi, Hesam
dc.contributor.authorSalles, Évila Lopes
dc.contributor.authorShin, Eunice
dc.contributor.authorJarrahi, Abbas
dc.contributor.authorCostigliola, Vincenzo
dc.contributor.authorKumar, Pritesh
dc.contributor.authorYu, Jack C.
dc.contributor.authorMorgan, John C.
dc.contributor.authorHess, David C.
dc.contributor.authorVaibhav, Kumar
dc.contributor.authorDhandapani, Krishnan M.
dc.contributor.authorBabak, Baban
dc.date.accessioned2023-11-28T17:01:25Z
dc.date.available2023-11-28T17:01:25Z
dc.date.issued2021-12
dc.identifier.citationKhodadadi, H., Salles, É. L., Shin, E., Jarrahi, A., Costigliola, V., Kumar, P., Yu, J. C., Morgan, J. C., Hess, D. C., Vaibhav, K., Dhandapani, K. M., & Baban, B. (2021). A potential role for cannabichromene in modulating TRP channels during acute respiratory distress syndrome. Journal of Cannabis Research, 3(1), Article 45. https://doi.org/10.1186/s42238-021-00101-0en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/624912
dc.description.abstractBackground: Acute respiratory distress syndrome (ARDS) is a life-threatening clinical syndrome whose potential to become one of the most grievous challenges of the healthcare system evidenced by the COVID-19 pandemic. Considering the lack of target-specific treatment for ARDS, it is absolutely exigent to have an effective therapeutic modality to reduce hospitalization and mortality rate as well as to improve quality of life and outcomes for ARDS patients. ARDS is a systemic inflammatory disease starting with the pulmonary system and involves all other organs in a morbid bidirectional fashion. Mounting evidence including our findings supporting the notion that cannabinoids have potential to be targeted as regulatory therapeutic modalities in the treatment of inflammatory diseases. Therefore, it is plausible to test their capabilities as alternative therapies in the treatment of ARDS. In this study, we investigated the potential protective effects of cannabichromene (CBC) in an experimental model of ARDS. Methods: We used, for the first time, an inhalant CBC treatment as a potential therapeutic target in a murine model of ARDS-like symptoms. ARDS was induced by intranasal administration of Poly(I:C), a synthetic mismatched double-stranded RNA, into the C57BL/6 mice (6–10 male mice/group, including sham, placebo, and CBC treated), three once-daily doses followed by a daily dose of inhalant CBC or placebo for the period of 8 days starting the first dose 2 h after the second Poly(I:C) treatment. We employed histologic, immunohistochemistry, and flow cytometry methods to assess the findings. Statistical analysis was performed by using one way analysis of variance (ANOVA) followed by Newman–Keuls post hoc test to determine the differences among the means of all experimental groups and to establish significance (p < 0.05) among all groups. Results: Our data showed that CBC was able to reverse the hypoxia (increasing blood O2 saturation by 8%), ameliorate the symptoms of ARDS (reducing the pro-inflammatory cytokines by 50% in lung and blood), and protect the lung tissues from further destruction. Further analysis showed that CBC may wield its protective effects through transient receptor potential (TRP) cation channels, TRPA1 and TRPV1, increasing their expression by 5-folds in lung tissues compared to sham and untreated mice, re-establishing the homeostasis and immune balance. Conclusion: Our findings suggest that inhalant CBC may be an effective alternative therapeutic target in the treatment of ARDS. In addition, Increased expression of TRPs cation channels after CBC treatment proposes a novel role for TRPs (TRPA1 and TRPV2) as new potential mechanism to interpret the beneficial effects of CBC as well as other cannabinoids in the treatment of ARDS as well as other inflammatory diseases. Importantly, delivering CBC through an inhaler device is a translational model supporting the feasibility of trial with human subjects, authorizing further research.en_US
dc.language.isoenen_US
dc.publisherBMC - Springer Natureen_US
dc.relation.url10.1186/s42238-021-00101-0en_US
dc.subjectARDSen_US
dc.subjectCBCen_US
dc.subjectCOVID-19en_US
dc.subjectCannabichromeneen_US
dc.subjectTRPA1en_US
dc.subjectTRPV1en_US
dc.titleA potential role for cannabichromene in modulating TRP channels during acute respiratory distress syndromeen_US
dc.typeAbstracten_US
dc.typeArticleen_US
dc.contributor.departmentAugusta Universityen_US
dc.identifier.journalJournal of Cannabis Researchen_US
refterms.dateFOA2023-11-28T17:01:28Z


Files in this item

Thumbnail
Name:
s42238-021-00101-0.pdf
Size:
1.432Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record